Immunic Inc (NAS:IMUX)
$ 1.27 -0.02 (-1.55%) Market Cap: 114.40 Mil Enterprise Value: 20.02 Mil PE Ratio: 0 PB Ratio: 1.37 GF Score: 41/100

Immunic Inc To Discuss Interim Data Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive MS Call Transcript

Oct 10, 2023 / 12:00PM GMT
Release Date Price: $1.37 (-13.84%)
Jessica Breu
Immunic, Inc. - Head of IR & Communications

Good morning to our audience today. I would like to welcome you to Immunic's webcast to present the positive interim data from our Phase II CALLIPER trial of vidofludimus calcium in patients with progressive multiple sclerosis, reported after the market closed yesterday.

My name is Jessica Breu, Head of Investor Relations and Communications at Immunic. I will also be the moderator on today's webcast. Speaking on the call are Dr. Daniel Vitt, our Chief Executive Officer and President; and Dr. Andreas Muehler, our Chief Medical Officer. (Operator Instructions) And this event is being recorded. After today's presentation, there will be an opportunity to ask questions. (Operator Instructions).

Before we begin, I would like to remind you that this presentation may contain forward-looking statements. Such statements can be identified by words such as may, will, expect, anticipate, estimate or words with similar meaning, and such statements involve a number of risks and uncertainties that could cause Immunic's actual results to

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot